 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jun 30, 2022 |
| Title |
Interactomics Analyses of Wild-type and Mutant A1CF Reveal Diverged Functions in Regulating Cellular Lipid Metabolism |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Population genetic studies highlight a missense variant (G398S) of A1CF that is strongly associated with higher levels of blood triglycerides (TGs) and total cholesterol (TC). Functional analyses suggest that the mutation accelerates the secretion of very low-density lipoprotein (VLDL) from the livers by an unknown mechanism. Here, we used multi-omics approaches to interrogate the functional difference between the WT and mutant A1CF. Using metabolomics analyses, we captured the cellular lipid metabolite changes induced by the transient expression of the proteins, confirming that the mutant A1CF is able to relieve the TG accumulation induced by WT A1CF. Using a proteomics approach, we obtained the interactomic data of WT and mutant A1CF. Networking analyses show that WT A1CF interacts with three functional protein groups, RNA/mRNA processing, cytosolic translation and, surprisingly, mitochondrial translation. The mutation diminishes these interactions, especially with the group of mitochondrial translation. Differential analyses show that the WT A1CF-interacting proteins most significantly different from the mutant are those for mitochondrial translation, whereas the most significant interacting proteins with the mutant are those for cytoskeleton and vesicle-mediated transport. RNA-seq analyses validate that the mutant, but not the WT, A1CF increases the expression of the genes responsible for cellular transport processes. On the contrary, WT A1CF affected the expression of mitochondrial matrix proteins and increased cell oxygen consumption. Thus, our studies confirm the previous hypothesis that A1CF plays broader roles in regulating gene expression. The interactions of the mutant A1CF with the vesicle-mediated transport machinery provide mechanistic insight in understanding the increased VLDL secretion in the A1CF mutation carriers.
|
| |
|
| Overall design |
Mutant A1CF vs. wild type
|
| |
|
| Contributor(s) |
Xu Y, Kathiresan S |
| Citation(s) |
32786677 |
| |
| Submission date |
Jun 19, 2020 |
| Last update date |
Sep 29, 2022 |
| Contact name |
Yu-Xin Xu |
| E-mail(s) |
[email protected]
|
| Phone |
6469198320
|
| Organization name |
Massachusetts General Hospital
|
| Department |
Center for Genomic Medicine
|
| Street address |
185 Cambridge Street Simches Research Building, CPZN 5.500
|
| City |
Boston |
| State/province |
United States |
| ZIP/Postal code |
02114 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA640523 |
| SRA |
SRP267948 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE152807_15373631438-2_Mutant-control_vs_Mutant-treated.gene_exp.diff.gz |
1.1 Mb |
(ftp)(http) |
DIFF |
| GSE152807_15373631438-2_Mutant-control_vs_Mutant-treated.gene_exp_significant.xlsx |
280.9 Kb |
(ftp)(http) |
XLSX |
| GSE152807_15373631438-2_WT-Control_vs_WT-Treated.gene_exp.diff.gz |
1.2 Mb |
(ftp)(http) |
DIFF |
| GSE152807_15373631438-2_WT-Control_vs_WT-Treated.gene_exp.diff_significant.xlsx |
72.0 Kb |
(ftp)(http) |
XLSX |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...